last edit us test vaneet
test adw note vaneet pleas ignor
eacci etokimab asthma updat consist prior result
downgrad under-perform
scrap june across board support fade
royal bank canada ry
nation bank canada na
canadian imperi bank commerc cm
scotia bn
montreal bmo
test note pleas ignor
labcorp america lh
relinquish crown
downgrad under-perform
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result
investor awar firm may conflict interest could affect object report investor consid report
singl factor make invest decis
strategi econom strategi
sinc septemb stock price experienc abrupt shift back flip-flop comment
fed direct rate administr state trade talk pattern
obscur substanti declin econom activ yield
major declin yield occur well presid
may tweet regard chines tariff similarli ism manufactur industri product
deterior sinc late summer global cyclic data disappoint well
past sever year weve held steadfast construct market call base belief
uninspir non-recessionari growth would lead elong cycl higher stock price
time weve regularli recommend period stress approach opportunist
question whether view still hold light softer econom
near-term incom data signal recess believ investor remain
cautiou long pace deceler remain steep recommend fade
news-flow-driven bounc sign greater econom stabil re-emerg
continu outperform growth top valu larg beat small
date product date dissemin
last edit us test vaneet
fail establish efficaci hs show signific dose respons
shine studi actual individu hiscr four differ activ dose fell
investor expect placebo respons unusu high lack separ
activ arm lack statist signific dose respons cast doubt
approach treatment hidraden suppurativa ifrx lead program
account vast major stock valu disappoint clinic setback
expect investor assign limited/no valu addit pipelin program believ stock
trade near/below cash consist previou grey sky scenario
downgrad under-perform lower tp slightli
compani cash valu lower probabl success
given clinic program smaller indic compani
product clinic develop also significantli reduc sg spend
ep estim vs assum on-going cash burn due hs trial wind
cost on-going trial aav pg risk under-perform thesi includ posit pipelin
develop and/or success execut strateg transact
date product date dissemin
downgrad under-perform
outperform
updat model follow earn modestli chang
ep estim td reflect slightli weaker margin canada modestli higher loan
loss ratio ep estim fall target price
base multipl ep
risk target price estim includ unexpect chang econom
condit either canada risk around market view potenti acquisit
manag suggest option given bank strong capit posit
neg turbul wholesal segment td
canadian bank report loss
date product date dissemin
price month
last edit us test vaneet
royal bank canada ry
updat model follow earn modestli chang ep
estim ry reflect slightli weaker margin canada modestli higher loan loss ratio
ep estim ep estim
target price base multipl
ep
risk target price estim includ chang econom condit
canada and/or weak bank us capit market busi
high level spend tech-rel initi uncertain payoff
date product date dissemin
nation bank canada na
updat model follow earn modestli chang ep
estim na reflect slightli weaker margin canada modestli higher loan loss ratio
ep estim ep estim
target price base multipl
risk target price estim includ unexpect chang econom
condit canada particularli within provinc quebec potenti regulatori chang
may impact bank capit posit given na higher exposur capit market
bank sensit equiti market debt market volatil
date product date dissemin
price month
price month
last edit us test vaneet
canadian imperi bank commerc cm
updat model follow earn modestli chang ep
estim cm reflect slightli weaker margin canada modestli higher loan loss ratio
ep estim goe ep estim
target price base
multipl ep
risk target price estim includ unexpect chang econom
condit canada and/or meaning margin eros cm tri recoup lost
market share shift bank strategi loss key execut
date product date dissemin
price month
scotia bn
updat model follow earn modestli chang ep
estim bn reflect slightli weaker margin canada modestli higher loan loss
ratio ep estim ep estim
target price base multipl
ep
risk target price estim includ unexpect materi chang econom
condit countri bn oper bnss intern platform expos
polit risk sever countri earn volatil due chang local market condit
challeng integr intern asset
date product date dissemin
price month
last edit us test vaneet
montreal bmo
updat model follow earn ep estim
ep estim target price base
multipl ep
risk target price estim includ unexpect posit neg materi
chang econom condit canada and/or given larg oper
regulatori chang neg impact bank capit posit market share
deterior sensit capit market condit given bmo rel sizabl wholesal
date product date dissemin
price month
action/ev bullet text hook report call stock read ii
chang rate target price materi forecast iii proprietari natur content
test note pleas ignor
invest overview bullet text market fail discount stock ii
catalyst risk bullet text upcom events/results/catalyst stock ii
potenti risk call
valuat bullet text relev valuat benchmarks/methodolog arriv target price
ii instrument consid
import note cover invest case narr store rave use
creat pb white-label report reason benefit institut client
cover must summari materi inform recommend report
contain abbreviations/acronym includ ticker compani subject
compani unless wide known first refer spell
also contain refer ib recommend list includ focu list except
grey banner text/figur includ later research report
addit contain copi past invest case narr store rave
use invest case titl
date product date dissemin
price month
last edit us test vaneet
test note
date product date dissemin
mdr award valu approxim morn mdr announc jv saipem
chiyoda award contract anadarko mozambiqu recal jv
previous perform feed project award scope includ two
train total namepl capac mtpa well util infrastructur
associ develop mdr announc portion contract
saipem announc separ releas scope approxim approxim
 split understand award well relat advanc payment
alreadi factor mdr guidanc provid earlier
scope primarili saipem mdr saipem announc indic compani
take lead role project per mdr two compani lead project manag
engin procur share respons on-sit construct manag
meanwhil chiyoda indic project scope includ advisori servic impli
compani involv direct construct develop mdr like benefit
reduc scope given recent award golden pass compani
run exxon mozambiqu develop well
fid still target month recal anadarko previous announc expect
announc fid project june mdr indic morn compani
reflect contract award backlog follow fid expect june howev
follow plan sale certain anadarko asset includ mozambiqu
develop total follow acquisit occident
date product date dissemin
last edit us test vaneet
fail establish efficaci hs show signific dose respons
shine studi actual individu hiscr four differ activ dose fell
investor expect placebo respons unusu high lack separ
activ arm lack statist signific dose respons cast doubt
approach treatment hidraden suppurativa ifrx lead program
account vast major stock valu disappoint clinic setback
expect investor assign limited/no valu addit pipelin program believ stock
trade near/below cash consist previou grey sky scenario
downgrad under-perform lower tp slightli
compani cash valu lower probabl success
given clinic program smaller indic compani
product clinic develop also significantli reduc sg spend
ep estim vs assum on-going cash burn due hs trial wind
cost on-going trial aav pg risk under-perform thesi includ posit pipelin
develop and/or success execut strateg transact
date product date dissemin
downgrad under-perform
outperform
labcorp america lh
relinquish crown
ceo retir remain chairman lh chairman ceo dave king retir
ceo role effect octob assum posit execut chairman current lead
independ director lh board sinc adam schechter succeed king ceo
thereaft end king admir extend ceo tenur decad jan
involv meaning evolut compani diversif strategi manag
chang admittedli earlier anticip particularli transit year lh
schechter recent departur merck dec follow relev career
compani recent presid divis repres
opportun amidst on-going success plan lh note king also current serv head
lh diagnost unit role expect fill come month recruit
thesi intact transit year lh view multipl avenu lt growth
across diversifi platform strong cf gener offer capit deploy flexibl
particularli relev given role lead consolid post-pama world
anticip activ beyond also continu view lh cro driver
estimate oper profit woefulli underappreci
date product date dissemin
price month
last edit us test vaneet
test adw note vaneet pleas ignor
number share mn
estimate pot chg tp
last edit us test vaneet
prior result
increment follow consist expect present today addit
follow data single-dos pbo-control eosinophil asthma trial updat
margin expect sinc compani previous report efficaci data day
etokimab led rapid improv lung function improv pbo day
day expect given single-dos design improv placebo
declin day asthma exacerb report day
exacerb report two pbo subject one etokimab subject post-day
patient receiv rescu therapi lead improv post day blood
eosinophil reduct biomark illustr etokimab effect remark consist
across indic roughli compar reduct singl dose atop
dermat asthma continu believ initi pbo-control data addit solid
biolog rational support explor etokimab eosinophil asthma
expect commenc larger multi-dos double-blind placebo-control
subject phase trial etokimab eosinophil asthma
catalyst-rich recent note bull versu bear debat discuss
upcom catalyst next anticip readout gpp readout
believ could serv increas floor stock ahead see
key catalyst etokimab data atop dermat crswnp data
expect note time revisit best-in-class potenti grow
atop market in-depth discuss evolv atop dermat market catch-up
competit landscap overal thought expect atop market evolv
date product date dissemin
last edit us test vaneet
scrap june across
channel check suggest shred scrap offici settl detroit
chicago pittsburgh june prime grade also across board amm
report end may mill cancel order may suggest anoth month
june fear sharp fall mitig recoveri turkish scrap valu season
strong demand level june fall much sharper expect drive spot
price lower medium term view platt report us smu
although understand larg size order closer would surpris
see us price offici move late summer especi automot trend
fair valu metal spread believ us metal spread near
stabl late-cycl demand environ especi broad-bas tariff relief
restart us capac remov canada mexico tariff trade
exempt substanti elimin volum tariff-bas us overal
trade climat support us industri scrap fall would peg
fair valu closer far recent spot price
season longer tailwind howev market set enter season softer
period month juli nov-dec destock exacerb recent price
fall automot market look weaker see demand-sid risk rise near term
furthermor cheap slab import canada start enter us market
jsw yet fulli ramp target volum level per month recent channel check
figur two month ago
fall scrap bullish long product eaf sharp fall us scrap price
bullish long product sector experienc solid demand growth
consolid past sever year beam rebar metal spread remain
elev level sharp fall scrap allow solid metal spread expans long product
plate even price discount also fabric busi see much higher
margin well long product price fall doubl benefit long scrap fall
faster sell price thu far case keep mind scrap
sinc reach lowest level us sinc
date product date dissemin
last edit us test vaneet
fed releas dfast result june ccar result june point
fast approach revisit ccar instruct scenario updat
dfast model order valid capit return expect consid
conserv interpret year scenario current etho fed
expect higher loss stress period suffici capac support
increas dollar amount net capit return cs larg cap bank
translat pay-out ccar
ccar sever advers scenario featur sever recess
compar last year scenario reflect feder reserv scenario design
framework call pronounc econom downturn current condit
especi strong compar last year scenario note normal path stress
observ extrem scenario gradual declin equiti
price credit spread widen declin long-term treasuri rate suggest potenti
attenu cost stress
earn power start take edg cost stress cs
larg cap bank come ccar process base rate earn power ppnr
estim last year level ii margin less regulatori capit averag
level still excess requir minimum support capac capit return
cost stress interpret ccar instruct translat
margin larger hit base case ppnr consist macro factor sever advers
scenario magnitud peak trough declin etc march ccar
transpar document ccar particip bank estim stress baselin
ppnr compar stress baselin ppnr ccar ii increas
stress provis expens iii reduct market-rel loss iv less
advers impact oci translat higher dollar amount stress
loss consid context capit level base rate earn power
stress level appear manag analysi indic cushion
minimum point factor capit return assumpt
date product date dissemin
last edit us test vaneet
charl martineau pm univers toronto compani mention price
montreal bmo
scotia bn
canadian imperi bank commerc cm
labcorp america lh
nation bank canada na
royal bank canada ry
